Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC5 | O15392 | 1/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | PRKCG | P05129 | 1/20 | 0.42 |
| ▸ | PRKCB | P05771 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | PRKACG | P22612 | 1/20 | 0.42 |
| ▸ | PRKACB | P22694 | 1/20 | 0.42 |
| ▸ | PRKCH | P24723 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4692987 | 0.81 | BIRC5 (0.70) | BIRC5CYP19A1ROCK2PIM1PIM3 | |
| SCHEMBL27745005 | 0.81 | BIRC5 (0.47) | BIRC5CHRNB2CHRNA4CYP19A1PRKD3 | |
| SCHEMBL29373675 | 0.78 | CHRNB2 (0.53) | BIRC5CHRNB2CHRNA4MAPT | |
| SCHEMBL5663553 | 0.78 | BIRC5 (0.66) | BIRC5ROCK2PIM1PIM3PRKD3 | |
| SCHEMBL29896808 | 0.78 | BIRC5 (0.66) | BIRC5ROCK2PIM1PIM3PRKD3 | |
| SCHEMBL8541169 | 0.78 | ALDH1A1 (0.43) | BIRC5CHRNB2CHRNA4CYP19A1PRKD3 | |
| SCHEMBL13166899 | 0.78 | BIRC5 (0.55) | BIRC5CHRNB2CHRNA4CYP19A1PRKD3 | |
| SCHEMBL2348013 | 0.76 | BIRC5 (0.53) | BIRC5CHRNB2CHRNA4CYP19A1PRKD3 | |
| SCHEMBL29725523 | 0.76 | BIRC5 (0.53) | BIRC5CHRNB2CHRNA4CYP19A1PRKD3 | |
| SCHEMBL29896937 | 0.75 | BIRC5 (1.00) | BIRC5CYP19A1ROCK2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897219-B2 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2005-05-24 | — | — | US | disclosed |
| EP-1274710-B1 | NOVEL HETEROARYL-DIAZABICYCLOALKANES | NEUROSEARCH AS (DK) | 2005-02-23 | — | — | EP | disclosed |
| US-6825189-B1 | TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION | NEUROSEARCH A/S (DK) | 2004-11-30 | — | — | US | disclosed |
| US-6815438-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | NEUROSEARCH A/S (DK) | 2004-11-09 | — | — | US | disclosed |
| EP-1027336-B1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH AS (DK) | 2004-10-06 | — | — | EP | disclosed |
| US-20040072823-A1 | Heteroaryl diazacycloalkanes, their preparation and use; | NEUROSEARCH A/S | 2004-04-15 | — | — | US | disclosed |
| EP-1274710-A2 | NOVEL HETEROARYL-DIAZABICYCLOALKANES | NeuroSearch A/S (DK) | 2003-01-15 | — | — | EP | disclosed |
| US-20030004153-A1 | Novel heteroaryl-diazabicycloalkanes | NEUROSEARCH A/S (DK) | 2003-01-02 | — | — | US | disclosed |
| WO-2001044243-A2 | NOVEL HETEROARYL-DIAZABICYCLOALKANES | NEUROSEARCH A/S (DK) | 2001-06-21 | — | — | WO | disclosed |
| EP-1027336-A1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021834-A1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004153-A1 | Novel heteroaryl-diazabicycloalkanes | CHRNA2, CHRNA5, CHRNA6 | BIRC5 2946/4885CHRNB2 6/4885CHRNA4 8/4885 |
| US-20040072823-A1 | Heteroaryl diazacycloalkanes, their preparation and use; | OGFR, CBR3, OGFRL1 | BIRC5 4562/4885CHRNB2 700/4885CHRNA4 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.